Lavifent (Fentanyl)

Fentanyl binds to mu‑opioid receptors in the brain and spinal cord, activating a cascade that reduces neuronal excitability and blocks transmission of pain signals. The patch’s matrix releases fentanyl slowly, providing sustained plasma levels that produce long‑lasting analgesia without the peaks and troughs associated with oral dosing.

The appropriate dose of Lavifent is set by the prescribing clinician based on factors such as the severity of the patient’s pain, prior opioid exposure, overall health status, and renal or hepatic function. The prescriber selects a patch strength that delivers the required amount of fentanyl over the intended wear period.

The safety of fentanyl patches in pregnancy and lactation has not been established. Because opioids can cross the placenta and may be excreted in breast milk, Lavifent is generally avoided unless the potential benefit justifies the potential risk. Consultation with a specialist is essential before use in these populations.

To request Lavifent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing a quotation, availability, shipping details, and any necessary import documentation.

Lavifent delivers fentanyl, a highly potent synthetic opioid, whereas other patches may contain buprenorphine or morphine, which have different potency and receptor profiles. Fentanyl’s high lipid solubility allows efficient transdermal absorption, offering rapid onset and strong analgesia, but it also requires careful monitoring for respiratory depression.

Lavifent should be stored at room temperature, below 25 °C, in its original pouch to protect it from light and moisture. Do not expose the patch to excessive heat or direct sunlight, and keep it out of reach of children and pets.

The patch is applied to a clean, dry, and intact area of skin on the upper torso or upper arm. Press the patch firmly for about 30 seconds to ensure good contact, then cover it with a protective dressing if needed. The patch remains in place for the prescribed wear period, typically 72 hours, after which a new patch is applied to a different site.

The most critical risks include respiratory depression, severe hypotension, and the potential for opioid dependence or abuse. In rare cases, life‑threatening skin reactions such as Stevens‑Johnson syndrome may occur. Patients should be monitored closely for signs of shallow breathing, excessive sedation, or allergic responses, and the patch should be removed immediately if serious adverse events develop.

Lavifent is contraindicated in individuals with known hypersensitivity to fentanyl or any patch components, those with severe respiratory insufficiency, untreated obstructive sleep apnea, or acute asthma attacks. It should also be avoided in patients who are not opioid‑tolerant, as well as in children and adolescents unless specifically prescribed by a specialist.